CM
HZNP

Crystalline Management’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Crystalline Management’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-54,845
Closed -$6.35M – 145
2023
Q3 		$6.35M Buy
54,845
+14,845
+37% +$1.6M 4.56% 5
2023
Q2 		$4.11M Sell
40,000
-10,000
-20% -$1.06M 2.91% 6
2023
Q1 		$5.49M Buy
50,000
+5,000
+11% +$553K 3.99% 8
2022
Q4 		$5.12M Buy
+45,000
New +$3.74M 2.57% 12

Other funds holding HZNP

IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return
VWA
Valued Wealth Advisors Holladay, Utah $247M AUM 21.93% 1-Year Est. Return
FSWA
Financial Synergies Wealth Advisors Houston, Texas $1.18B AUM 31.41% 1-Year Est. Return
BCMLT
Beacon Capital Management LLC (Tennessee) Franklin, Tennessee $567M AUM 16.01% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Crystalline Management's HZNP Position: Q4 2023 in Review

Crystalline Management sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2023, closing a stake of 54,845 shares — an estimated $6.35M sold.

Crystalline Management first reported a position in HZNP in Q4 2022 and held it in 4 quarters. The position peaked at $6.35M in Q3 2023. 6 funds tracked by Wall St. Rank hold HZNP as of Q4 2023.

  • Crystalline Management reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2023 after selling out during the quarter.
  • Crystalline Management sold 54,845 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2023, an estimated $6.35M.
  • Crystalline Management first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2022 and held it in 4 quarters.
  • Crystalline Management's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $6.35M in Q3 2023.
  • 6 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2023.

Based on Crystalline Management's 13F filing for Q4 2023, filed 12 Feb 2024.